PAVM - PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

PAVmed ([[PAVM]] -1.1%) and its major subsidiary Lucid Diagnostics announce that Lucid’s EsoCheck Esophageal Cell Collection Device with Collect + Protect technology has received CE Mark certification. With this certification, EsoCheck may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland, and Lichtenstein), Switzerland, and, until July 1, 2023, the U.K. EsoCheck is an FDA-cleared swallowable balloon capsule catheter, which allows a clinician to sample surface cells from the esophagus in a less than 5-minute non-invasive procedure.

For further details see:

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device